Trends in hospitalizations related to anaphylaxis, angioedema and urticaria in the united states (2001-2014)
There are limited data for prevalence of allergic disorders over time. Recent studies have noted marked increase in prevalence of allergic conditions over different parts of the world. We sought to examine time trends in the prevalence of anaphylaxis, angioedema and urticaria in the US. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: P. Shrestha, R. Dhital, D. Poudel, A. Donato, P. Karmacharya, T. Craig Tags: A150 Source Type: research

Acei vs. non-acei induced angioedema: when to intubate?
Angioedema is a life-threatening condition requiring immediate medical intervention, especially when it involves the oropharynx. Angiotensin converting enzyme inhibitors (ACEi) are one of the most common causes of angioedema. The purpose of this study was to elucidate the difference in clinical features and outcome of patients with ACEi induced angioedema versus other causes, and identify intubation predictors. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: C. Cheah, K. Dass, A. Guthrie, B. Dalal Tags: A151 Source Type: research

Lanadelumab 300mg every 2 weeks effectively prevented hereditary angioedema attacks in the help study
Lanadelumab, a highly specific, fully human monoclonal antibody targeting plasma kallikrein, demonstrated sustained and well-tolerated prophylaxis against hereditary angioedema (HAE) attacks in the phase 3 HELP Study (NCT02586805). Three dosing regimens were investigated; here we report further efficacy findings for lanadelumab 300mg every 2 weeks (q2wks). (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: A. Banerji, M. Riedl, B. Zuraw, W. Lumry, P. Lu, J. Hao, M. Maurer, H. Li Tags: A152 Source Type: research

Effects of omalizumab on markers of type 2 inflammation: results from the extra study
We examined the impact of omalizumab on T2 inflammatory biomarkers. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: B. Chipps, T. Casale, M. Yang, C. Holweg, T. Haselkorn, N. Griffin, N. Hanania Tags: A200 Source Type: research

Factors associated with early readmission in acute asthma exacerbation - results from national readmission database
Asthma exacerbations are an important cause of emergency department visits. The 30-day readmission rate, which is a marker of asthma severity, remains substantial. The aim of our study was to assess demographic and clinical factors associated with early asthma readmissions. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: R. Dhital, I. Mir, P. Shrestha, S. Basnet, D. Poudel Tags: A201 Source Type: research

Effect of omalizumab on seasonal exacerbations in adolescents and adults with moderate-to-severe allergic asthma
The Inner-City Anti-IgE Therapy for Asthma (ICATA) study showed that seasonal asthma exacerbation patterns, with peaks in fall and spring, were largely eliminated in children with persistent asthma after omalizumab treatment. This effect has not been examined in adolescents/adults. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: J. Corren, T. Casale, T. Haselkorn, M. Yang, A. Iqbal, B. Ortiz, W. Busse Tags: A202 Source Type: research

Epithelial cell gene networks upregulated in obese asthmatic children
Obesity is a major pediatric health concern affecting almost 20% of American children and adolescents. Obesity is a risk factor for the development of asthma and is associated with increased asthma severity. Children with obesity and asthma have reduced responsiveness to inhaled corticosteroids, increased use of systemic corticosteroids during exacerbations, and a reduced FEV1/FVC ratio. The mechanisms underlying the influence of obesity on asthma pathogenesis remain poorly understood. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: A. Huang, C. Swanson, D. Babineau, E. Whalen, M. Gill, B. Shao, A. Liu, B. Jepson, R. Gruchalla, G. O'Connor, J. Pongracic, C. Kercsmar, G. Khurana Hershey, E. Zoratti, C. Johnson, S. Teach, M. Kattan, L. Bacharier, A. Beigelman, S. Sigelman, P. Gergen, L Tags: A203 Source Type: research

A multidisciplinary severe asthma clinic for pediatric patients: review of the first 12 months experience
A combined pediatric Pulmonary Allergy Problematic Asthma (PAPA) clinic was developed to provide multidisciplinary care for children with severe/difficult-to-treat asthma, identified by PCP referral or a “high utilizer” label from the inpatient unit at the time of third hospitalization in 12-month time-frame at a tertiary care Pediatrics hospital. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: P. Capucilli, B. Amos, J. Ewig, S. DaVeiga Tags: A204 Source Type: research

Frequency of improper inhaler technique identified by electronic medication monitor (emm) actuation timing
This study aimed to detect inadequate inhalation technique by quantifying the time between two consecutive actuations using EMMs that passively collected time and date of use. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: W. Anderson, H. Hoch, R. Gondalia, L. Kaye, B. Theye, M. Barrett, D. Van Sickle, S. Szefler, D. Stempel Tags: A205 Source Type: research

Dupilumab efficacy in uncontrolled, moderate-to-severe allergic asthma in the phase 3 liberty asthma quest study
Dupilumab, a fully human interleukin (IL)-4 receptor- α monoclonal antibody inhibiting IL-4/IL-13 signaling pathways, key drivers of Type 2 inflammation, is approved for treating adults with inadequately controlled moderate-to-severe atopic dermatitis. In the phase 3 LIBERTY ASTHMA QUEST study (NCT02414854), dupilumab 200mg and 300mg administered ever y 2 weeks versus matched placebo reduced annualized severe exacerbation rates and improved pre-bronchodilator forced expiratory volume in 1 second (FEV1) and quality-of-life measures, and was generally well tolerated in patients with uncontrolled, moderate-to-severe ast...
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: M. Castro, J. Corren, N. Hanania, I. Pavord, S. Quirce, K. Thangavelu, M. Rice, T. O'Riordan, J. Maroni, P. Rowe, Y. Lu, N. Amin, M. Ruddy, B. Akinlade, N. Graham, A. Teper Tags: A206 Source Type: research

Eosinophil levels, exacerbations, resource utilization and costs among moderate-to-severe asthma patients
In the US, ∼900,000 patients (≥12 years) have uncontrolled moderate-to-severe asthma despite using available treatments. Elevated eosinophils (EOS) are a marker of Type-2 asthma; however, their association with asthma exacerbations, healthcare resource utilization (HCRU) and costs has not been well describ ed in a real-world setting. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: J. Graham, J. Chao, U. Mallya, A. Khan, S. Kamat, P. Simonelli Tags: A207 Source Type: research

Caregiver knowledge as a predictor of length of stay in children hospitalized with asthma exacerbations ¶
Asthma is a leading cause of hospitalizations and missed school days in children. We hypothesized that poor caregiver knowledge about asthma would be associated with a longer length of stay in children hospitalized with an asthma exacerbation. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: D. Deshpande, H. Phan, M. Borgstrom, R. Miller, M. Brown Tags: A208 Source Type: research

Use of spirometry for diagnosis and management of asthma in a community health center
Guidelines recommend spirometry for diagnosing and managing asthma, but previous reports suggest that spirometry is underused, especially in patients who are nonwhite, lower income, or cared for by primary care (rather than subspecialist) physicians. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: A. Amirneni, P. Roychowdhury, J. Badwal, T. Lagu, D. Singh Tags: A209 Source Type: research

Rituximab associated antibody dysfunction in b cell non-hodgkin's lymphoma
Rituximab is an anti-CD20 chimeric antibody used to treat B cell neoplasms and autoimmune conditions. Although it is well known that rituximab can cause persistent hypogammaglobulinemia, there is no standardized approach to evaluate immune dysfunction in patients treated with rituximab. We characterized immunoglobulin levels and vaccine responses in rituximab-treated B cell non-Hodgkin's lymphoma patients. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: S. Mustafa, A. Ramsey, S. Jamshed Tags: A250 Source Type: research

Immunoglobulin therapy and quality of life in primary immunodeficiency patients with non-infectious pulmonary complications
This study aims to examine rates of non-infectious pulmonary complications in patients with common variable immunodeficiency (CVID) and the impact of immunoglobulin replacement therapy (IRT) on quality of life (QOL) in this patient subset. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: A. Checkley, S. Kile, L. Kristofek, W. Bolgar, L. Seidu Tags: A251 Source Type: research

Comprehensive clinical and immunological features of adult selective primary igm deficiency: response to immunoglobulin therapy
Selective IgM Deficiency (SIGMD) is a recently incorporated primary immunodeficiency. Clinical and immunological features have been reported in a small number of cases. The aim of this study is to present comprehensive clinical immunological features in a large cohort of adult patients diagnosed with SIGMD, and to assess response to Ig therapy. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: D. Lucuab-Fegurgur, S. Gupta Tags: A252 Source Type: research

Underrecognition of primary immunodeficiencies in the adult population in a tertiary care facility
Primary immunodeficiency (PID) diseases present in patients with decreased function of the innate and/or adaptive immune systems. PID patients can develop symptoms after a normal childhood. Unfortunately, the general awareness of PIDs in the adult population remains low. The following study examined the degree of recognition by general physicians for PIDs in adult patients when clinically indicated. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: J. Oh, J. Fernandez Tags: A253 Source Type: research

Evaluating behavioral problems in patients with primary immunodeficiency disorders within the us immunodeficiency network registry
Primary immunodeficiency (PID) encapsulates various disorders with diverse phenotypes. Its burden of disease has the potential to impact the emotional well-being of patients. The purpose of this study is to evaluate the psychosocial impact of PID using data from the US Immunodeficiency Network (USIDNET) national registry. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: J. Jose, K. Sullivan Tags: A254 Source Type: research

Galactose-a-1,3-galactose sensitization and the a-gal syndrome: characteristics of subjects seeking emergency care
Galactose - α-1,3- galactose (α-Gal) is an oligosaccharide of non-primate mammals and the culprit allergen in a syndrome of delayed anaphylaxis to mammalian meat (ie, α-Gal syndrome). We sought to describe the clinical presentations of a large cohort of subjects from Central Virginia, with or without IgE to α-Gal, who presented for emergent care for allergic reactions. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: M. Gupta, A. Schuyler, L. Workman, S. Commins, T. Platts-Mills, J. Wilson Tags: A300 Source Type: research

Peanut allergen immunotherapy: online education improves knowledge of allergist learners
A study was conducted to determine if an online educational intervention could improve knowledge and competence of allergists in the latest research on peanut allergen immunotherapies. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: N. Mehta, S. Dermer Tags: A301 Source Type: research

Quantitative risk reduction through epicutaneous immunotherapy (epit): results from the pepites phase iii trial
Peanut allergy prevalence is increasing world-wide and currently no FDA-approved treatment is available. Epicutaneous immunotherapy (EPIT) with Viaskin Peanut (VP250) is being studied in peanut-allergic subjects using a novel single-dose (250 microgram peanut protein) patch. Phase II and III clinical trials have demonstrated a statistically significant benefit of VP250 over placebo through increased eliciting doses on double-blind, placebo-controlled food challenges (DBPCFC). As cross-contamination exposures to peanut through packaged goods are a leading concern and cause of allergic reactions, we aimed to quantify "r...
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: B. Remington, T. Krone, S. Koppelman Tags: A302 Source Type: research

Increased reactivity threshold in peanut-allergic subjects treated with 12 months of epicutaneous viaskin peanut
Peanut-allergic patients receiving immunotherapy seek to increase their sensitivity threshold to peanut protein, which is associated with a risk reduction to accidental peanut consumption. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: T. Green, C. Davis, R. Lambert, J. Bird Tags: A303 Source Type: research

Development and preliminary validation of the nima peanut sensor: a consumer device for food testing
For individuals with peanut allergy, a peanut-free diet is the recommended strategy for avoiding illness. However, undetermined amounts of allergens in foods of unknown origin make it difficult to strictly adhere to this practice. Described is validation testing to evaluate performance of a newly developed portable peanut sensor for foods. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: A. Burt, J. Artiuch, E. Chun, M. Cipriani, A. Leung, A. Scutari, L. Slakey, S. Wilson, F. Dias Lourenco, S. Yates Tags: A304 Source Type: research

Serum biomarkers of immunomodulation during peanut epicutaneous immunotherapy (epit) in peanut-allergic subjects
In a Phase 3, randomized, double-blind, placebo-controlled trial in children 4-11 years, daily EPIT with 250 µg peanut patch (VP-250) was superior to placebo (p = 0.00001) in proportion of responders (based on peanut double-blind, placebo-controlled food challenge threshold change) after application for 12 months. We evaluated biomarkers differentiating VP-250 vs. placebo subjects. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: M. Greenhawt, W. Carr, C. Davis, J. Lieberman, S. Mustafa, T. Green, P. Gramme, R. Lambert, D. Fleischer Tags: A305 Source Type: research

Early peanut introduction in the primary care setting
This study evaluates primary care provider (PCP) understanding of the current NIH recommendations on early peanut introduction. By identifying knowledge gaps, we can target future interventions to improve practical application of the guidelines. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: P. Mehta, C. Malloy, M. DeFelice, H. Gordon Tags: A306 Source Type: research

Triggers and severity of anaphylaxis in infants
We examined causes, clinical features and severity of infant anaphylaxis. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: A. Blackman, S. Anvari, A. Anagnostou Tags: A307 Source Type: research

Application of oral immunotherapy (oit) clinical trial endpoints to a real-world setting
Double-blind, placebo-controlled food challenges (DBPCFCs) are the gold standard for the diagnosis of food allergy and are being used as clinical trial endpoints for new food allergy therapies. We sought to determine how these endpoints translate into meaningful data that the practicing allergist can use. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: E. Sher, C. Ciaccio, N. Griffin, K. Rosen, B. Chipps Tags: A308 Source Type: research

Increased incidence and prevalence of peanut allergy in children and adolescents in the united states
Peanut allergy (PA) is associated with high rates of severe reactions and impaired quality of life, yet epidemiologic data are limited. Utilizing a real-world, nationally representative cohort of children/adolescents, we examined incidence and prevalence of PA. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: J. Lieberman, J. Sublett, Y. Ali, T. Haselkorn, V. Damle, A. Chidambaram, K. Rosen, T. Mahr Tags: A309 Source Type: research

The epidemiology of milk allergy in us children: an update
This study looks at the epidemiological pattern of childhood milk allergy in the US, including diagnosis, symptoms, severity, and tolerance to baked milk. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: C. Warren, S. Duck, A. Mukherjee, W. Samady, B. Smith, M. Kanaley, R. Gupta Tags: A310 Source Type: research

Prevalence, severity, and distribution of adult-onset food allergy
While much attention has been devoted to food allergy in children, little is known about the prevalence and characteristics of food allergy in adults. Moreover, recent research has shown that increasing numbers of individuals are developing food allergy in adulthood. This population-based study was conducted to examine the prevalence, severity, and distribution of adult-onset food allergy. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: C. Warren, C. Stankey, J. Jiang, J. Blumenstock, B. Smith, R. Gupta Tags: A311 Source Type: research

Updated pediatric peanut allergy prevalence in the united states
This study aims to further elucidate the current state of peanut allergy in the United States. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: J. Jiang, O. Bushara, J. Ponczek, C. Warren, J. Blumenstock, B. Smith, R. Gupta Tags: A312 Source Type: research

Oral desensitization to peanut using ar101 peanut oral immunotherapy in a roll-over safety study arc002
This phase 2, open-label trial was designed to study the safety and tolerability of long-term AR101 exposure in peanut-allergic subjects. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: J. Bird, M. Welch, J. Spergel, S. Jones, R. Rachid, J. Wang, A. Assa'ad, B. Vickery, N. Griffin, K. Brown, T. Pham, J. Matthews, A. Burks Tags: A313 Source Type: research

Methicillin-resistant staphylococcus aureus and clostridium difficile infections among penicillin-allergic patients in a university hospital
In this study, we compare the prevalence of Methicillin-resistant Staphylococcus aureus (MRSA) and Clostridium difficile infections among patients with a reported PCN allergy to that of PCN non-allergic patients. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: J. Galant-Swafford, T. Lin, X. Tu, S. Christiansen, A. Kim Tags: A350 Source Type: research

Antibiotic allergies in patients with and high risk for neutropenia: a quality improvement opportunity
Standard therapy for patients with neutropenic fever is treatment with an antipseudomonal antibiotic. Patients with a history of self-reported penicillin allergy are often given alternative antibiotic regimens; however, up to 90% of these patients do not have IgE-mediated hypersensitivity and thus are inappropriately labeled as allergic. The effects of documented penicillin allergy on outcomes have been recognized: higher hospital charges, increased risk for surgical complications, and recently, increased rates of clostridium difficile infection and mortality in patients with hematologic malignancies. (Source: Annals of Al...
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: M. Straesser, D. Khokhar, W. Eschenbacher, L. Donohue, A. Ebers, J. Eby, M. Keng, L. Borish, T. Kyin Tags: A351 Source Type: research

Efficient identification and clearance of low-risk penicillin allergy patients
While penicillin allergy is commonly reported, proven penicillin allergy is rare. Clearance of penicillin allergy benefits patients and public health.   We sought to identify our population's penicillin allergy clearance rate and extend current data regarding safety of oral challenge to amoxicillin without prior penicillin skin testing. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: D. Lindsey, T. Banks Tags: A352 Source Type: research

A randomized, double-blind, placebo-controlled trial of anti-interleukin-13 monoclonal antibody rpc4046 in patients with eosinophilic esophagitis
This study evaluated efficacy and safety of 2 dose levels of RPC4046 compared to placebo (PBO). (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: I. Hirano, M. Collins, Y. Assouline-Dayan, L. Evans, S. Gupta, A. Schoepfer, A. Straumann, C. Rodriguez, S. Hua, E. Dellon Tags: A400 Source Type: research

Adverse event profile of sq house dust mite sublingual immunotherapy tablet after treatment interruption
The SQ house dust mite (HDM) sublingual immunotherapy (SLIT)-tablet is approved for  daily administration for the treatment of HDM-induced allergic rhinitis. The adverse event (AE) profile following treatment interruption was evaluated. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: S. Tilles, H. Nelson, B. Prenner, J. Maloney, I. Mosbech Smith, H. Nolte Tags: A450 Source Type: research

Serum ige reactivity to cross-reacting molecules in pollen allergic patients from north eastern poland
This study assesses the prevalence of sensitization to profilins, polcalcins and CCDs in seasonal allergic rhinitis patients (ARs). (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: K. Kowa, A. Pampuch, E. Sacharzewska, L. DuBuske Tags: A451 Source Type: research

Eds-flu versus traditional nasal steroids for treating chronic rhinosinusitis: summarizing current evidence for symptom benefits
Standard intranasal steroids (INS) are first-line therapy, but yield limited benefit, in treating defining symptoms of CRSw/sNP (congestion, rhinorrhea, facial pain/pressure, anosmia). We compared symptom relief with traditional INS, as summarized in a 2016 Cochrane review, with symptom relief reported in pooled trials with EDS-FLU (exhalation delivery system with fluticasone). (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: G. Bensch, J. Messina, H. Sacks, R. Mahmoud Tags: A452 Source Type: research

Eds-flu (exhalation delivery system with fluticasone) benefits on nasal polyp disease relative to monoclonal antibodies
We report the effect of EDS-FLU on outcomes in a subgroup of patients with similar polyp burden to those enrolled in mAb studies. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: N. Parikh, B. Chipps, J. Messina, J. Carothers, H. Sacks, R. Mahmoud Tags: A453 Source Type: research

Staphylococcus aureus induces antimicrobial reg3g and tslp production by nasal epithelium ¶
One theory to persistent inflammation seen in CRS is recurrent infection due to inability to destroy bacteria. Nasal epithelium provides first line defense in differentiating pathogenic from commensal bacteria. Increased permeability of nasal epithelium, decreased antimicrobial production and impaired mucociliary clearance are features of CRS. Although 30% of people are colonized with Staphylococcus aureus, colonization does not lead to infection until epithelial barrier is disrupted. Majority of CRS patients have positive MRSA cultures. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: S. Choi Tags: A454 Source Type: research

A systematic review and meta-analysis of depression and suicide in atopic dermatitis
The objective of this study was to determine the complex relationship between AD and depression. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: K. Patel, S. Immaneni, V. Singam, S. Rastogi, J. Silverberg Tags: A500 Source Type: research

The c-159t polymorphism of the cd-14 gene and cytokine profiles in adults with atopic dermatitis
A C-to-T transition has been identified at position 159 in the promoter region of the CD14 gene. This functional single-nucleotide polymorphism C-159T has been associated with high levels of IgE and allergy. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: O. Litus, N. Derkach, V. Litus, Y. Bisyuk, L. DuBuske Tags: A501 Source Type: research

Diagnostic accuracy of allergen component sige in childhood peanut and hazelnut allergy: meta analysis results
Specific IgE antibodies to peanut and hazelnut allergen components can help distinguish between symptomatic and clinically irrelevant sensitizations. We investigated the utility of peanut and hazelnut components in allergy diagnosis through a systematic approach, analyzing the diagnostic accuracy of sIgE to storage proteins and pollen cross-reactive PR-10 proteins. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: M. Berthold, B. Mascialino, S. Sj ölander, C. Nilsson, R. Hamilton Tags: D100 Source Type: research

Rescue medication use reduction with benralizumab for patients with severe, uncontrolled eosinophilic asthma
We investigated the effect of benralizumab, an interleukin-5 receptor alpha –directed cytolytic monoclonal antibody, on rescue medication use by patients with severe, uncontrolled asthma with eosinophilic inflammation. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: S. O'Quinn, X. Xu, I. Hirsch Tags: D200 Source Type: research

Observational vignette study to examine patient, healthcare provider, and caregiver perceived burden of asthma-related exacerbations
This study examined the burden of asthma-related exacerbations on patients ’ lives from these different perspectives. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: C. Averell, P. Johnson, C. Bell, J. White, B. Essoi, L. Nelsen Tags: D201 Source Type: research

Asthma control among individuals with and without comorbid allergies
The prevalence of allergic asthma (AA) among patients with asthma is significant. We evaluated the differences in asthma control in patients with asthma with and without comorbid allergies in a managed care population. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: B. Ortiz, P. Sullivan, M. Lanz, V. Ghushchyan, A. Kavati, J. LeCocq, D. Maselli Tags: D202 Source Type: research

Ak002, a novel siglec-8 antibody depletes human eosinophils and inhibits anaphylaxis in humanized mice
Pathologic accumulation and over-activation of mast cells and eosinophils have been implicated in certain allergic and inflammatory diseases. Siglec-8 is an inhibitory receptor selectively expressed on human eosinophils, mast cells, and, to a significantly lesser extent, basophils. Antibodies to Siglec-8 have the potential to be broadly anti-inflammatory by inducing apoptosis of eosinophils and inhibiting mast cell activation. AK002 is a novel, humanized, non-fucosylated IgG1 monoclonal antibody to Siglec-8. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: A. Chang, B. Youngblood, E. Brock, R. Falahati, P. Bryce, M. Brehm, J. Leung, C. Bebbington, N. Tomasevic Tags: D400 Source Type: research

Impact of chronic rhinosinusitis with nasal polyposis on quality of life by sino-nasal surgery history
The objective of this study was to assess the impact of CRSwNP on HRQoL among patients with disease refractory to maximal medical treatment, defined by history of sino-nasal surgery. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: A. Khan, T. Huynh, S. Kamat, L. Mannent, P. Tomassen, T. Van Zele, L. Cardell, J. Arebro, H. Olze, U. Foerster-Ruhrmann, M. Kowalski, A. Olszewska-Ziaber, W. Fokkens, C. van Drunen, J. Mullol, I. Alobid, P. Hellings, V. Hox, E. Toskala, G. Scadding, V. Lu Tags: D450 Source Type: research

Cost-effectiveness of eds-flu in sinus surgery candidates who have chronic rhinosinusitis with nasal polyps
This study compared the modeled costs and quality adjusted life year (QALY) gains with surgery vs. (Source: Annals of Allergy, Asthma and Immunology)
Source: Annals of Allergy, Asthma and Immunology - November 1, 2018 Category: Allergy & Immunology Authors: F. Velez, H. Sacks, J. Messina, D. Malone, N. Smith, R. Mahmoud Tags: D451 Source Type: research